Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Genprex ( (GNPX) ).
On January 6, 2026, Genprex reported positive preliminary preclinical data for its gene therapy candidate GPX-002 in Type 2 diabetes, showing in vivo proof-of-concept in both non-human primates and mice. In Type 2 diabetic non-human primates, infusion of an AAV vector carrying Pdx1 and MafA genes into the pancreatic duct led over several months to normalized glucose tolerance in one severely diabetic animal, alongside reduced insulin requirements, while a second animal receiving direct pancreatic injection showed significant but less complete improvement. The studies also highlighted that a defined period of immunosuppression is needed in primates to counter immune responses to AAV, with early findings suggesting AAV protein expression lasts six months or less, informing future dosing and safety strategies. In mouse models of Type 2 diabetes, intraductal infusion of GPX-002 without immunosuppression rejuvenated exhausted beta cells, restored glucose-stimulated insulin secretion, reversed hyperglycemia and normalized glucose levels within four weeks, further supporting the therapy’s mechanism of action. Collectively, these data strengthen Genprex’s broader diabetes program in both Type 1 and Type 2 indications, support continued preclinical development and planned toxicology work ahead of regulatory filings, and suggest potential for GPX-002 to expand the company’s reach to the large Type 2 diabetes population, while underscoring that preclinical results may not be replicated in later clinical trials.
More about Genprex
Genprex, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for diabetes and oncology, with a focus on using adeno-associated viral (AAV) vectors to reprogram pancreatic cells for the treatment of Type 1 and Type 2 diabetes. Its lead diabetes candidate, GPX-002, is designed to be delivered directly into the pancreatic duct, aiming either to transform alpha cells into insulin-producing beta-like cells in Type 1 diabetes or to rejuvenate and replenish exhausted beta cells in Type 2 diabetes, potentially addressing the vast majority of diabetes patients worldwide.
Average Trading Volume: 757,512
Technical Sentiment Signal: Sell
Current Market Cap: $4.17M
For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.